OCUL
Ocular Therapeutix, Inc
$10.20
-0.34 (-3.23%)
At close · Jul 10
Market Cap
$2.23B
Shares
218,960,358
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$51.95M
-18.5%
FY2025
Net Income
-$265.94M
-37.4%
FY2025
Gross Margin
87.35%
-3.8pp
FY2025
Operating Margin
-519.75%
-250.2pp
FY2025
Diluted EPS
-$1.42
-16.4%
FY2025
Operating Cash Flow
-$204.88M
-52.1%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $52.04M | $51.95M | $63.72M | $58.44M | $51.49M | $43.52M | $17.4M | $4.23M | $1.99M | $1.92M | $1.89M | $1.75M | $772K | |
| $6.64M | $6.57M | $5.63M | $5.28M | $4.54M | $4.41M | $2.08M | $2.33M | — | $457K | $443K | $319K | $91K | |
| $45.4M | $45.38M | $58.1M | $53.16M | $46.95M | $39.12M | $15.32M | $1.9M | — | $1.47M | $1.44M | $1.43M | $681K | |
| — | 87.35% | 91.17% | 90.96% | 91.18% | 89.88% | 88.03% | 45% | — | 76.24% | 76.52% | 81.77% | 88.21% | |
| $220.45M | $197.1M | $127.64M | $61.06M | $53.46M | $50.08M | $28.69M | $41.09M | $36.92M | $30.88M | $27.07M | $26.61M | $18.88M | |
| $56.35M | $53.92M | $41.59M | $40.55M | $39.92M | $35.19M | $26.61M | $24.49M | $4.94M | $17M | $6.7M | $3.85M | $1.98M | |
| $68.03M | $64.38M | $60.65M | $33.94M | $32.22M | $31.88M | $22.86M | $22.12M | $18.79M | $15.51M | $11M | $9.17M | $6.91M | |
| — | $4.32M | $3.79M | $2.98M | $2.11M | $2.42M | $2.77M | $2.53M | $2.29M | $1.63M | $881K | $754K | $547K | |
| — | — | — | — | — | — | — | $2.51M | $2.51M | $2.51M | — | — | — | |
| $43.38M | — | — | — | — | — | — | — | — | — | — | $39.95M | $27.87M | |
| $351.48M | $321.97M | $235.5M | $140.83M | $130.15M | $121.56M | $80.25M | $90.03M | $61.11M | $63.85M | $45.21M | — | — | |
| -$299.44M | -$270.02M | -$171.78M | -$82.38M | -$78.65M | -$78.04M | -$62.85M | -$85.8M | -$59.12M | -$61.92M | -$43.33M | -$38.2M | -$27.09M | |
| — | -519.75% | -269.57% | -140.96% | -152.74% | -179.3% | -361.13% | -2029.86% | -2970.75% | -3220.12% | -2296.03% | -2182.69% | -3509.59% | |
| — | -$265.69M | -$168M | -$79.4M | -$76.55M | -$75.62M | -$60.07M | -$83.27M | -$56.83M | -$60.3M | -$42.45M | -$37.44M | -$26.55M | |
| $11.63M | $11.84M | $13.58M | $11.34M | $7.02M | $6.67M | $6.77M | $6.1M | $1.74M | $1.89M | $1.68M | $1.72M | $1.12M | |
| $8.94M | $4.08M | -$21.73M | $1.65M | $7.62M | $71.48M | -$92.79M | -$570K | -$860K | -$1.46M | -$1.38M | -$1.55M | -$1.55M | |
| — | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | |
| -$290.5M | -$265.94M | -$193.51M | -$80.74M | -$71.04M | -$6.55M | -$155.64M | -$86.37M | -$59.98M | -$63.39M | -$44.7M | -$39.75M | -$28.65M | |
| — | -511.9% | -303.67% | -138.14% | -137.95% | -15.06% | -894.31% | -2043.34% | -3013.97% | -3296.2% | -2369% | -2271.31% | -3710.88% | |
| — | -$80.74M | -$80.74M | -$80.74M | -$71.04M | -$6.55M | — | — | — | — | -$44.7M | -$39.75M | -$28.66M | |
| — | — | — | — | — | — | — | -$86.37M | -$59.98M | -$63.38M | -$44.64M | -$39.82M | — | |
| USD/shares | — | -$1.42 | -$1.22 | -$1.01 | -$0.92 | -$0.09 | — | -$0.53 | — | — | — | — | — |
| USD/shares | — | -$1.42 | -$1.22 | -$1.02 | -$0.97 | -$0.98 | — | -$0.53 | — | — | — | — | — |
| shares | — | 187.24M | 158.27M | 79.83M | 76.88M | 76.39M | 60.75M | 45.27M | 38.12M | 28.82M | 24.82M | 23.24M | 10.65M |
| shares | — | 187.24M | 158.27M | 85.6M | 82.64M | 82.16M | 60.75M | 45.27M | 38.12M | 28.82M | 24.82M | 23.24M | 10.65M |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against the industry, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Biotechnology median 8.05×
EV/EBIT
—
Biotechnology median 25.73×
P/E (TTM)
—
Biotechnology median 7.52×
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Single Reportable Segment | $51,951,000 | $63,723,000 | $58,443,000 | $51,494,000 |
By Product & Service (USD)
| Component | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|---|
| Product | $51,823,000 | $63,461,000 | $57,870,000 | $50,457,000 | $43,522,000 | $17,403,000 |
| Collaboration Revenue | $128,000 | $262,000 | $573,000 | $1,037,000 | — | — |